CLD-101 is a novel stem cell-based treatment that delivers oncolytic viruses to tumors, which may benefit patients with newly ...

New study shows that the lengths of menstrual cycles, follicular phases (before egg release) and luteal phases (after ovulation) are all variable. The luteal phase is importantly more variable than ...

Yufei Liu, MD, PhD, discussed the importance of careful data interpretation to accurately assess the efficacy of new ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

KaliVir Immunotherapeutics has dosed the first subject in a Phase I/Ib clinical trial for its new oncolytic immunotherapy, ...

KEYTRUDA’s safety profile in this trial was found to be in line with previous studies, without any new safety concerns ...

AdAlta (ASX:1AD) has formed a clinical advisory board and appointed an additional adviser to advance its lead asset AD-214.

More research on clinical meaningfulness is on the way, according to Stephanie Graff, M.D., FACP, FASCO, director of breast oncology at the Lifespan Cancer Institute and author of Investigating the ...

Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases –– Cardiovascular Scientific ...

The investigational IL-17A inhibitor izokibep was found to induce clear clinical responses in people with moderate to severe ...

BioAtla faces a tight cash runway until Q3 2025, raising concerns about dilution and short-term stock headwinds. Find out why ...